Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis

Y. Yawata, R. Howe, H. S. Jacob

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A plasma factor that inhibits red cell hexose monophosphate (HMP) shunt metabolism and thereby shortens red cell survival was found to accumulate in roughly half of uremic patients. The factor is efficiently removed by frequent hemodialysis with purified water in the bath solutions. However, contaminants in tap water hemodialysis baths potentiate the red cell defect, and hemolysis may strikingly worsen in patients so dialyzed. As in patients with deficient red cell glucose 6 phosphate dehydrogenase, and thus deficient HMP shunt metabolism, explosive Heinz body hemolytic anemia may occur in affected uremic patients given oxidant drugs, such as sulfonamides, antimalarials, and the like. The authors urge that uremic patients be screened for red cell HMP shunt deficiency before administration of sulfonamides or other oxidant compounds and that affected patients be dialyzed only against purified water baths.

Original languageEnglish (US)
Pages (from-to)362-367
Number of pages6
JournalAnnals of Internal Medicine
Volume79
Issue number3
DOIs
StatePublished - Jan 1 1973

Fingerprint

Uremia
Hemolysis
Renal Dialysis
Pentose Phosphate Pathway
Water
Baths
Sulfonamides
Oxidants
Glucosephosphate Dehydrogenase
Hemolytic Anemia
Antimalarials
Cell Survival
Pharmaceutical Preparations

Cite this

Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis. / Yawata, Y.; Howe, R.; Jacob, H. S.

In: Annals of Internal Medicine, Vol. 79, No. 3, 01.01.1973, p. 362-367.

Research output: Contribution to journalArticle

@article{8858b52c7b9747c1bd05950498b87132,
title = "Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis",
abstract = "A plasma factor that inhibits red cell hexose monophosphate (HMP) shunt metabolism and thereby shortens red cell survival was found to accumulate in roughly half of uremic patients. The factor is efficiently removed by frequent hemodialysis with purified water in the bath solutions. However, contaminants in tap water hemodialysis baths potentiate the red cell defect, and hemolysis may strikingly worsen in patients so dialyzed. As in patients with deficient red cell glucose 6 phosphate dehydrogenase, and thus deficient HMP shunt metabolism, explosive Heinz body hemolytic anemia may occur in affected uremic patients given oxidant drugs, such as sulfonamides, antimalarials, and the like. The authors urge that uremic patients be screened for red cell HMP shunt deficiency before administration of sulfonamides or other oxidant compounds and that affected patients be dialyzed only against purified water baths.",
author = "Y. Yawata and R. Howe and Jacob, {H. S.}",
year = "1973",
month = "1",
day = "1",
doi = "10.7326/0003-4819-79-3-362",
language = "English (US)",
volume = "79",
pages = "362--367",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis

AU - Yawata, Y.

AU - Howe, R.

AU - Jacob, H. S.

PY - 1973/1/1

Y1 - 1973/1/1

N2 - A plasma factor that inhibits red cell hexose monophosphate (HMP) shunt metabolism and thereby shortens red cell survival was found to accumulate in roughly half of uremic patients. The factor is efficiently removed by frequent hemodialysis with purified water in the bath solutions. However, contaminants in tap water hemodialysis baths potentiate the red cell defect, and hemolysis may strikingly worsen in patients so dialyzed. As in patients with deficient red cell glucose 6 phosphate dehydrogenase, and thus deficient HMP shunt metabolism, explosive Heinz body hemolytic anemia may occur in affected uremic patients given oxidant drugs, such as sulfonamides, antimalarials, and the like. The authors urge that uremic patients be screened for red cell HMP shunt deficiency before administration of sulfonamides or other oxidant compounds and that affected patients be dialyzed only against purified water baths.

AB - A plasma factor that inhibits red cell hexose monophosphate (HMP) shunt metabolism and thereby shortens red cell survival was found to accumulate in roughly half of uremic patients. The factor is efficiently removed by frequent hemodialysis with purified water in the bath solutions. However, contaminants in tap water hemodialysis baths potentiate the red cell defect, and hemolysis may strikingly worsen in patients so dialyzed. As in patients with deficient red cell glucose 6 phosphate dehydrogenase, and thus deficient HMP shunt metabolism, explosive Heinz body hemolytic anemia may occur in affected uremic patients given oxidant drugs, such as sulfonamides, antimalarials, and the like. The authors urge that uremic patients be screened for red cell HMP shunt deficiency before administration of sulfonamides or other oxidant compounds and that affected patients be dialyzed only against purified water baths.

UR - http://www.scopus.com/inward/record.url?scp=0015814190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015814190&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-79-3-362

DO - 10.7326/0003-4819-79-3-362

M3 - Article

VL - 79

SP - 362

EP - 367

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -